NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?

Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shilpa, Kamat, Ashish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338128/
https://www.ncbi.nlm.nih.gov/pubmed/32632305
http://dx.doi.org/10.1038/s41585-020-0357-1
_version_ 1783554613636497408
author Gupta, Shilpa
Kamat, Ashish M.
author_facet Gupta, Shilpa
Kamat, Ashish M.
author_sort Gupta, Shilpa
collection PubMed
description Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care Excellence (NICE) approval was based on efficacy data, but the final appraisal report rejected use of pembrolizumab owing to treatment cost.
format Online
Article
Text
id pubmed-7338128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73381282020-07-07 NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good? Gupta, Shilpa Kamat, Ashish M. Nat Rev Urol News & Views Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care Excellence (NICE) approval was based on efficacy data, but the final appraisal report rejected use of pembrolizumab owing to treatment cost. Nature Publishing Group UK 2020-07-06 2020 /pmc/articles/PMC7338128/ /pubmed/32632305 http://dx.doi.org/10.1038/s41585-020-0357-1 Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News & Views
Gupta, Shilpa
Kamat, Ashish M.
NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
title NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
title_full NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
title_fullStr NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
title_full_unstemmed NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
title_short NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
title_sort nice’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338128/
https://www.ncbi.nlm.nih.gov/pubmed/32632305
http://dx.doi.org/10.1038/s41585-020-0357-1
work_keys_str_mv AT guptashilpa nicesrejectionofpembrolizumabforplatinumrefractoryurothelialcarcinomaisthereagreatergood
AT kamatashishm nicesrejectionofpembrolizumabforplatinumrefractoryurothelialcarcinomaisthereagreatergood

Ejemplares similares